Table 2.
Association with Mortality of Clinical Characteristics, Comorbidities, Lung Function, and Treatment by Cox Regression Analysis
| Univariable Analysis |
Multivariable Analysis |
|||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Sex, M/F | 4.22 (1.47–12.06) | 0.01 | 3.90 (1.17–13.04) | 0.03 |
| Age, yr | 1.07 (1.03–1.10) | <0.01 | 1.07 (1.04–1.11) | <0.01 |
| Body mass index, kg ⋅ m−2 | 1.02 (0.96–1.09) | 0.51 | — | — |
| Underlying ILD, fibrotic/other | 2.15 (1.06–4.35) | 0.04 | — | — |
| Comorbidities, yes/no | ||||
| Obesity | 1.01 (0.41–2.47) | 0.99 | — | — |
| Hypertension | 2.48 (1.18–5.21) | 0.02 | — | — |
| Cardiovascular disease | 3.20 (1.55–6.59) | <0.01 | — | — |
| Diabetes mellitus | 1.46 (0.69–3.06) | 0.32 | — | — |
| Chronic kidney disease | 1.81 (0.63–5.20) | 0.27 | — | — |
| Cancer or hemopathy | 3.21 (1.12–9.21) | 0.03 | 5.82 (1.88–18.08) | <0.01 |
| Pulmonary hypertension | 2.88 (1.22–6.83) | 0.02 | — | — |
| Pulmonary characteristics | ||||
| FVC% predicted | 0.98 (0.96–0.99) | 0.02 | — | — |
| Corrected DlCO% predicted | 0.96 (0.94–0.99) | <0.01 | — | — |
| Oxygen supplementation at home | 4.25 (2.02–8.91) | <0.01 | 4.56 (2.13–9.78) | <0.01 |
| Treatment at baseline, yes/no | ||||
| Antifibrotic medication | 3.09 (1.27–7.55) | 0.01 | — | — |
| Glucocorticoids | 1.06 (0.51–2.18) | 0.88 | — | — |
| Immunosuppressive drugs | 0.58 (0.26–1.30) | 0.19 | — | — |
| COVID-19–related medications, yes/no | ||||
| Any | 1.43 (0.70–2.92) | 0.32 | — | — |
| Lopinavir/ritonavir | 1.61 (0.49–5.30) | 0.43 | — | — |
| Azithromycine | 0.23 (0.03–1.72) | 0.15 | — | — |
| Hydroxychloroquine | 1.58 (0.60–4.11) | 0.35 | — | — |
| Glucocorticoids | 1.15 (0.40–3.28) | 0.80 | — | — |
Definition of abbreviations: CI = confidence interval; COVID-19 = coronavirus disease; HR = hazard ratio; ILD = interstitial lung disease. Bold indicates P < 0.05.